Evidence map›Paper›PMID 35282065›Full record

ArticleAnnals of translational medicine2022

Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report.

Guotao Fang, Weiwei Liu, Yanhong Shang, Ran Huo, Xiaoliang Shi, Yanan Wang, Jinghua Li

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Guotao Fang *Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Weiwei Liu *Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Yanhong ShangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Ran HuoDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Xiaoliang ShiOrigiMed Co. Ltd, Shanghai, China.
Yanan WangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Jinghua LiMedical Office, Affiliated Hospital of Hebei University, Baoding, China.
Affiliated Hospital of Hebei University · CNUnimed Medical Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated significant survival benefits for advanced non-small cell lung cancer (NSCLC) patients with sensitive EGFR mutations. However, patients with EGFR-TKI treatment often develop acquired resistance subsequently. Transformation from NSCLC to small cell lung cancer (SCLC) is a rare EGFR-TKI resistance mechanism for patients with sensitive

Indexed as

acquired resistanceAdenocarcinomacase reportepidermal growth factor receptor (EGFR)small cell lung cancer (SCLC)

Identifiers

PMID35282065
PMCPMC8848416
OpenAlexW4210635890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.